Contrast Agent Market Size Analysis, Industry Outlook, & Region Forecast, 2023-2032

6 minutes, 0 seconds Read

The global contrast agent market size was USD 5.3 Billion in 2022 and is expected to register a revenue CAGR of 6% over the forecast period, according to the latest report by Reports and Data.

The World Health Organization (WHO) estimated that cancer caused 9.6 million deaths in 2018, making it the second leading cause of death globally. The demand for contrast agents is anticipated to increase along with the incidence of cancer because contrast-enhanced imaging methods, like computed tomography (CT) and magnetic resonance imaging (MRI), are widely used for cancer diagnosis.

The advancement of imaging technologies has also greatly aided the market’s growth. High-resolution imaging systems and novel contrast agents with enhanced properties like stability, biocompatibility, and specificity have helped to increase the accuracy and efficacy of diagnostic techniques. A further factor driving the growth of global revenue is the complete transformation of the contrast agent market brought about by the incorporation of artificial intelligence (AI) into imaging technologies.

The FDA’s Center for Drug Evaluation and Research (CDER) establishes regulatory requirements for the approval of new contrast agents.

The FDA requires contrast agent manufacturers to conduct clinical trials and provide information on product labels, such as indications for use and contraindications.

Get a sample of the report @

Some of the prominent players profiled in the global contrast agent market include Guerbet SA, Lantheus Medical Imaging Inc, Bayer AG, Bracco Imaging S.p.A, JB Chemicals & Pharmaceuticals Ltd, GE Healthcare, Mallinckrodt Pharmaceuticals, Subhra Pharma Private Limited, Beekley Medical, DAIICHI SANKYO COMPANY LIMITED, and Shenzhen Anke High-tech Co. Ltd.

Some Key Highlights from the Report

  • In 2021, the gadolinium-based segment held the largest market share. Gadolinium-based contrast agents are frequently used during Magnetic Resonance Imaging (MRI) procedures due to their excellent image contrast qualities. The market for gadolinium-based contrast agents is growing due to the increasing prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular diseases, all of which require the use of contrast agents for proper diagnosis.
  • In 2021, the X-ray/CT segment secured the predominant portion of the revenue share. This outcome can be attributed to the prevalent utilization of X-ray and CT scans in diagnosing and monitoring various medical conditions. The market has been categorized into distinct segments including X-ray/CT, MRI, ultrasound, and others, categorized by modality.
  •  In terms of revenue, the North American market dominated the global contrast agent market in 2021. Due to the rising prevalence of chronic diseases, the rising demand for early diagnosis, and the accessibility of cutting-edge imaging techniques, the market in this region is expected to grow at the quickest rate in terms of revenue over the forecast period. The rising adoption of diagnostic imaging procedures and the existence of significant market players in this area are further factors that are expected to support the expansion of the North American contrast agent market.
  • In 2021, GE Healthcare and VUMC (Vanderbilt University Medical Center) announced a new research collaboration with the goal of developing safer and more effective contrast agents for medical imaging. The development of new MRI contrast agents will be the primary focus of this collaboration, which will aid in disease detection and treatment.
  • Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) and Bracco Imaging S.p.A. formed a strategic partnership in 2020 to expand Bracco’s presence in China. The main focus of this collaboration will be the development, production, and marketing of contrast agents for medical imaging in China.
  • Lantheus Medical Imaging, Inc. announced the release of a novel contrast agent, DEFINITY® microbubble contrast agent, in 2021. It is recommended to use DEFINITY® during echocardiography procedures to improve visibility of the left ventricular chamber and delineation of the endocardial border.
  • JB Chemicals & Pharmaceuticals Ltd. introduced OmnipaqueTM, a novel contrast agent, in 2020. OmnipaqueTM, a non-ionic iodinated contrast agent, is recommended for use in radiography treatments to make bodily organs and tissues more visible.

For the purpose of this report, Reports and Data has segmented the global contrast agent market on the basis of Product Type Outlook, Modality Outlook, Route of Administration Outlook, and Regional Outlook:

Product Type Outlook (Revenue, USD Billion; 2022 – 2032)

  • Iodinated Contrast Agent
  • Gadolinium-based Contrast Agents
  • Microbubble Contrast Agents
  • Others

Modality Outlook (Revenue, USD Billion; 2022 – 2032)

  • X-ray/CT Contrast Agents
  • Intravenous Contrast Agents
  • Rectal Contrast Agents
  • Others

Route of Administration Outlook (Revenue, USD Billion; 2022 – 2032)

  • Oral Contrast Agents
  • Intravenous Contrast Agents
  • Rectal Contrast Agents
  • Others

Regional Outlook (Revenue, USD Billion; 2022-2032)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel
    • Rest of MEA

Request a customization on the report @

Thank you for taking the time to read our article. The report can be tailored to the needs of the client. Please contact us for more details, and our team will tailor the report to your specific requirements.

Explore Trending Links:

Acute Lymphoblastic Leukemia Drug Market Size 2022-2028: Increasing Adoption Of Western Lifestyles, Including Dietary Modifications And Sedentary Lives –

Laboratory Information Management Systems (LIMS) Market Growth 2022-2028: The Surging Need for Improving the Efficiency of Lab Operations is a Key Factor –

Digital Therapeutics Market Trends 2022-2028: Investments for R&D to Explore Newer Sectors for Application and Launch of Products with Improved Quality –

Biological Safety Testing Market Scope 2022-2028: Rising Incidences of Chronic Disorders, Innovations in Treatment and Growth in Number of Healthcare Facilities Globally –

Remote Patient Monitoring Market Size 2022-2027- Surge In Incidence Of Coronavirus –

Temporary Pacemaker Market Share, Size, Key Players, Trends, Competitive And Regional Forecast To 2028 –

Post-Surgical Pain Treatment Market Demand –

Diabetic Gastroparesis Market Growth –

Binge Eating Disorder Treatment Market Analysis –


About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyse consumer behaviour shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Power and Energy, and Chemicals. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release:

Browse Upcoming Reports:

Browse Press Release:

Similar Posts